Helix training protocol file is located at the bottom of this page.
-------------------
Led by Melanie Tsang and I presume Jayaraman, we will soon be joining the HeLiX Trial.
This trial’s aim is to test TXA as a way to reduce blood transfusion in liver resection.
It’s headed up by a group from Sunnybrook and the General.
Stuart McCluskey and Jordan Tarshis are the anesthesia leads.
They’ve already been doing this trial for about three years.
I’ve agreed to be the anesthesia lead for St. Joe’s.
I’ve attached the protocol for your curiosity.
In brief, adult patients having any sort of liver resection are eligible with some standardized exclusion criteria.
By the time patients get to us in Pre-Admit, they will already have been recruited.
Our role will be intraoperative.
We’ll be handed a syringe (TXA vs. placebo) to administer followed by an infusion.
We’ll have to follow published transfusion criteria.
Reviewing the protocol, one thing caught my eye.
I found the exclusion criteria very limited as it pertains to history of thrombosis, more specifically:
“Documented arterial or venous thrombosis at screening or in past three months (not including therapeutic portal vein embolization)”
I took this up with Stuart telling him that this seemed pretty liberal.
He said that he had the same initial thoughts but after inquiring about it felt comfortable with it.
Following the criteria, there would be no exclusion of, for example, those with a history of CAD, coronary stents or CVA regardless of how recent.
There is an exclusion for those on NOAC’s and Coumadin.
Let me know if you have questions. Is there more info that I should obtain to clarify things?
Peter